Published in:
01-06-2015 | Erratum
Erratum to: Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem
Published in: International Journal of Clinical Pharmacy | Issue 3/2015
Login to get accessExcerpt
In the original publication, an incorrect Table 2 (Table 1 duplicated) has been published inadvertently. The correct Table 2 is given in this erratum.
Table 2
Clinical characteristics of patients with meropenem-associated convulsions
|
No.
|
Patient characteristics
(sex, age, eGFR)
|
Daily dosing schedule
|
Time of symptoms
(days from start of cefepime)
|
Symptoms and signs
|
Baseline disease
|
Anticonvulsant agent
|
Final assessment
|
|---|---|---|---|---|---|---|---|
|
A
|
F, 42,
95 mL/min
|
0.5 g every 8 h
|
2
|
Clonic convulsion
|
Cerebral infarction
|
Phenytoin (iv), valproic acid (po)
|
Administer thiamylal, and then complete resolution
|
|
B
|
M, 59,
106 mL/min
|
0.5 g every 8 h
|
2
|
Clonic convulsion
|
Encephaloma
|
None
|
Administer diazepam intravenously, and then complete resolution
|
|
C
|
F, 74,
69 mL/min
|
1 g every 12 h
|
2
|
Myoclonus
|
Multiple cerebral infarction
|
Clonazepam (po)
|
Administer diazepam intravenously, but uncontrollable convulsion, and then complete resolution
|
|
D
|
F, 39,
76 mL/min
|
1 g every 12 h
|
2
|
Clonic convulsion and decreased level of consciousness
|
B- cell lymphoma
(infiltration brain), febrile neutropenia
|
Zonisamide (po)
|
Administer diazepam intravenously, and then complete resolution after the discontinuation of meropenem
|